Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976142 | 0.99 | RXFP1 (0.53) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL196744 | 0.92 | MAPT (0.58) | RXFP1MAPTNPC1RAB9AGAA | |
| SCHEMBL196310 | 0.91 | RXFP1 (0.47) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL196063 | 0.91 | RXFP1 (0.60) | RXFP1MAPTNPC1RAB9AGAA | |
| SCHEMBL959149 | 0.91 | RXFP1 (0.53) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL196512 | 0.90 | MAPT (0.55) | RXFP1MAPTNPC1RAB9AGAA | |
| SCHEMBL934924 | 0.89 | IGF1R (0.52) | RXFP1MAPTTP53NPC1RAB9A | |
| SCHEMBL937298 | 0.88 | MAPT (0.64) | MAPTTP53RAB9AKMT2ANPSR1 | |
| SCHEMBL196681 | 0.87 | RXFP1 (0.53) | RXFP1MAPTNPC1RAB9AGAA | |
| SCHEMBL1848663 | 0.86 | CLK1 (0.50) | RXFP1MAPTTP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | claimed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | claimed |
| US-9668959-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2017-06-06 | — | — | US | disclosed |
| EP-2456419-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD (IL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160136079-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2016-05-19 | — | — | US | disclosed |
| US-9199102-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2015-12-01 | — | — | US | disclosed |
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | RXFP1 1376/4885MAPT 4299/4885TP53 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.